Giulia Lori
Overview
Explore the profile of Giulia Lori including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
202
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pranzini E, Muccillo L, Nesi I, Santi A, Mancini C, Lori G, et al.
Cell Death Discov
. 2024 Dec;
10(1):510.
PMID: 39706853
Cancer cachexia is a multifactorial syndrome characterized by a progressive loss of body weight occurring in about 80% of cancer patients, frequently representing the leading cause of death. Dietary intervention...
2.
Lori G, Pastore M, Navari N, Piombanti B, Booijink R, Rovida E, et al.
JHEP Rep
. 2024 Oct;
6(10):101182.
PMID: 39430578
Background & Aims: Among the reprogrammed metabolic pathways described in cancer stem cells, aberrant lipid metabolism has recently drawn increasing attention. Our study explored the contribution of fatty acids (FA)...
3.
Sasia C, Borgonetti V, Mancini C, Lori G, Arbiser J, Taddei M, et al.
Cells
. 2024 Oct;
13(19.
PMID: 39404415
Microglia-mediated neuroinflammation has been linked to neurodegenerative disorders. Inflammation and aging contribute to microglial senescence. Microglial senescence promotes the development of neurodegenerative disorders, including Alzheimer's disease (AD). In this study,...
4.
Mancini C, Lori G, Pranzini E, Taddei M
Trends Endocrinol Metab
. 2023 Dec;
35(3):263-276.
PMID: 38071164
Resistance to anticancer therapy still represents one of the main obstacles to cancer treatment. Numerous components of the tumor microenvironment (TME) contribute significantly to the acquisition of drug resistance. Microenvironmental...
5.
Caligiuri A, Gitto S, Lori G, Marra F, Parola M, Cannito S, et al.
Cancers (Basel)
. 2022 Sep;
14(17).
PMID: 36077744
Primary liver cancers represent the third-most-common cause of cancer-related mortality worldwide, with an incidence of 80-90% for hepatocellular carcinoma (HCC) and 10-15% for cholangiocarcinoma (CCA), and an increasing morbidity and...
6.
Correnti M, Cappon A, Pastore M, Piombanti B, Lori G, Oliveira D, et al.
Liver Int
. 2021 Sep;
42(1):233-248.
PMID: 34478594
Background And Aims: Cholangiocarcinoma (CCA) is a form of primary liver cancer with limited therapeutic options. Recently, cancer stem cells (CSCs) have been proposed as a driving force of tumour...
7.
Balboni F, Terreni A, Gallo M, Guzzi F, Caparrini C, Burbui S, et al.
Scand J Clin Lab Invest
. 2021 May;
81(5):418-421.
PMID: 34057879
GEM Premier ChemSTAT is a whole-blood analyzer designed for providing a rapid basic metabolic panel, inclusive of creatinine and blood urea nitrogen, with the unique characteristic of providing measured bicarbonate...
8.
Gentilini A, Lori G, Caligiuri A, Raggi C, Maira G, Pastore M, et al.
Hepatology
. 2021 May;
74(4):2007-2020.
PMID: 33959996
Background And Aims: Cholangiocarcinoma (CCA) is characterized by high resistance to chemotherapy and poor prognosis. Several oncogenic pathways converge on activation of extracellular signal-regulated kinase 5 (ERK5), whose role in...
9.
Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma
Raggi C, Taddei M, Sacco E, Navari N, Correnti M, Piombanti B, et al.
J Hepatol
. 2021 Jan;
74(6):1373-1385.
PMID: 33484774
Background & Aims: Little is known about the metabolic regulation of cancer stem cells (CSCs) in cholangiocarcinoma (CCA). We analyzed whether mitochondrial-dependent metabolism and related signaling pathways contribute to stemness...
10.
Grimaudo S, Bartesaghi S, Rametta R, Marra F, Mancina R, Pihlajamaki J, et al.
Liver Int
. 2020 Oct;
41(2):321-332.
PMID: 33091218
Background And Aims: The proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in cholesterol homeostasis, and its inhibition represents an effective therapy to lower low-density lipoprotein cholesterol (LDL-C)...